VEGFA and neoplasm: Malignant ascites is widely recognized as a poor prognostic marker, with median survival averaging approximately 20 weeks after diagnosis [14], This unfavorable prognosis is likely related to tumor-derived vascular endothelial growth factor (VEGF) and associated mediators that increase vascular permeability [15–17].